LabGenius: London-based startup gets €11.5M for discovering next-gen drugs using AI
London-based drug discovery company, LabGenius has announced today that it has raised over $10 million (€11.5 million) in its Series A financing round.
The growth in Artificial Intelligence (AI) has proliferated into various sectors. A lot of startups across the world are creating new approaches and seeking after the inventive business models in a bid to alter the pharmaceutical businesses.
LabGenius has announced today that it has raised over $10 million (€11.5 million) in its Series A financing round. LabGenius is a drug discovery company that is using artificial intelligence (AI), robotic automation, and synthetic biology to discover novel protein therapeutics.
The Series A investment round was led by Lux Capital and Obvious Ventures, with participation from Felicis Ventures, Inovia Capital, Gigafund, Air Street Capital and existing investors. The round also included participation from Recursion Pharmaceuticals’ Founder & CEO Chris Gibson as well as Inovia Capital General Partner Patrick Pichette who was formerly Google’s CFO. Zavain Dar, Partner at Lux Capital and Nan Li, Managing Director at Obvious Ventures, will join the company’s board of directors.
Protein therapeutics have an unparalleled potential to both treat disease and alleviate human suffering. By transforming how these drugs are discovered, we have a shot at improving the lives of countless people. Being able to robustly engineer novel therapeutic proteins has immense commercial and societal value. The discovery of protein therapeutics has historically been highly artisanal, relying heavily on humans for both experimental design and execution. This dependence has proved limiting because, as a species, we’re cognitively incapable of fully grasping the complexity of biological systems.
Zavain Dar, Partner at Lux Capital, said:
We have high conviction that computational approaches to protein engineering hold tremendous promise. After researching the space and meeting many companies, we believe that LabGenius is the clear breakout leader. We are beyond excited to co-lead the Series A and help the company realize their very ambitious vision to discover new protein therapies using AI.
— Press release
Stay tuned to Silicon Canals for more European technology news.
How money, ownership, and power actually move behind the companies you think you know. Built for people who watch our documentaries. Sundays you also get The Undercurrent.
Written by
Akansha Srivastava
Akansha Srivastava previously served as Silicon Canals' Editor in Chief.
A typical tech trend follower. Favourite job: analyzing the global tech industry. A true camera geek, gadget lover and travel enthusiast.
You can reach her via editors@siliconcanals.com.